Key facts

Invented name
Active substance
  • DNA plasmid encoding HPV type 16 consensus E6 and E7 proteins (pGX3001)
  • DNA plasmid encoding HPV type 18 consensus E6 and E7 proteins (pGX3002)
Therapeutic area
Infectious diseases
Decision number
PIP number
Pharmaceutical form(s)
Intramuscular use
Condition(s) / indication(s)
Treatment of squamous intraepithelial lesions of the cervix caused by HPV types 16 and 18
Route(s) of administration
Solution for injection (in cartridge)
Contact for public enquiries
Inovio Pharmaceuticals Inc.
United States
E-mail: jrichardson@inovio.com
Tel.: +1 2674404211
Decision type
W: decision granting a waiver in all age groups for all conditions/indications


How useful was this page?

Add your rating